Dr. John Cush RheumNow
9 months 3 weeks ago
High Cost of Cancelling Knee Replacement Surgery
Thousands of NHS knee replacement operations are cancelled at short notice every year, many for avoidable reasons, according to a new study published December 1st. This costs the NHS millions of pounds and increases waiting times https://t.co/USWAPC0k6N
Dr. John Cush RheumNow
9 months 3 weeks ago
ICYMI: Inflammatory vs. Noninflammatory Pain
https://t.co/3nJ2NZYTQY https://t.co/7FuSYzkX2G
Dr. John Cush RheumNow
9 months 3 weeks ago
Changing Loan Limits for Advance Practice Providers
The "One Big Beautiful Bill" (OBBB), or H.R. 1, was signed into law in July, calls for significant changes in the funding of healthcare education. This bill that lowers cap limits on education loans applies to graduate (APRN, https://t.co/4fwhAo2WG5
Dr. John Cush RheumNow
9 months 4 weeks ago
Legislative Issues Affecting APPs
Major interstate “compacts” allow for cross state licensing for physicians. However, compacts for Advanced Practice Registered Nurse (APRN) are fewer and currently on hold - thereby limiting healthcare manpower and patient care. https://t.co/sBYtX03IY7
Dr. John Cush RheumNow
9 months 4 weeks ago
Hiring, Onboarding and Training APPs
Watch our kickoff webinar for this month's Mission: APP — Partners in Care campaign. Our panel of rheumatologists and experienced advanced practice providers share insights into hiring, onboarding, training, compensation, and more. https://t.co/stgTQM9soW
Dr. Jack Cush reviews the news and journal reports from RheumNow.com, including info on scleroderma, dermatomyositis and malignancy, rheumatologist and APP salary concerns.
Dr. John Cush RheumNow
9 months 4 weeks ago
QD Clinic: Flare or Beware
Lindsay Tom, PA-C and Phong Nguyen, MD, Reston, VA discuss today's case called "Flare or Beware", involving a patient who has psoriatic arthritis mutilans, presented as part of RheumNow's "Mission: APP Partners in Care" campaign during the month of https://t.co/JbyHBCQ4ct
Dr. John Cush RheumNow
9 months 4 weeks ago
Survey of 500 Rheum Patients, 37% reported having APPs (NP or PA) as primary rheum providers. APP patients had greater ease scheduling& more prefer to see APPs over rheumatologists (P < 0.01) & recommend APPs . No difference between MD vs APP experience https://t.co/VShREnhsMG https://t.co/glaIUPZ5qh
Dr. John Cush RheumNow
9 months 4 weeks ago
RheumNow Live 2026
Where the data meets the dialogue.
Join leading rheumatologists, researchers, and innovators at RheumNow Live 2026 — the meeting redefining rheumatology education.
➡️https://t.co/zYYC2350tE https://t.co/4Vz7swwqFJ
Medscape recently reviewed off-label use of low dose naltrexone (LDN) in fibromyalgia (FM) and found it is deemed effective by some clinicians and patients, but 1) there is no FDA indication for LDN use in FM and 2) the data supporting its use is limited.
Dr. John Cush RheumNow
9 months 4 weeks ago
Retrospective cohort study of 546 DM or clinically amyopathic DM pts. 5 factors were signif assoc w/ cancers (1 point ea): 1) TIFF-1-γ Ab (OR 3.8), poikiloderma (OR 3.1), DM subtype (2.8), anemia (2.4), but ILD was protective (OR 0.39). Markedly elevated DM cancer risk seen w/ https://t.co/r564RbZys2
Use of disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA) was markedly lower among all major racial-ethnic minority groups in the U.S. compared with white patients, analysis of federal survey data indicated, even after adjusting for income, education, and other factors.
Dr. John Cush RheumNow
9 months 4 weeks ago
Consensus Definitions on Difficult to Treat PsA
A substantial number of patients with PsA, have difficult, persistent and hard-to-treat disease. A GRAPPA task force has developed a consensus terminology for two distinct states:
Complex-to-manage PsA (C2M-PsA) https://t.co/po1psn9GNm
